---
title: Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory
  Multiple Myeloma
date: '2024-10-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39365257/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20241004202124&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'Ciltacabtagene autoleucel (cilta-cel) CAR-T therapy was approved in
  2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes
  with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent
  leukapheresis for cilta-cel manufacturing between 3/1/2022-12/31/2022 at 16 US academic
  medical centers were included. RESULTS: 255 patients underwent leukapheresis and
  236 (92.5%) received cilta-cel. Of leukapheresed patients, 56% would not have met
  ...'
disable_comments: true
---
Ciltacabtagene autoleucel (cilta-cel) CAR-T therapy was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for cilta-cel manufacturing between 3/1/2022-12/31/2022 at 16 US academic medical centers were included. RESULTS: 255 patients underwent leukapheresis and 236 (92.5%) received cilta-cel. Of leukapheresed patients, 56% would not have met ...